Journal article · 2026 · Open access

From a single phenolic precursor to an all-in-one therapeutic cascade: Spatially programmed photoenzymatic immunotherapy and deep-tumor metabolic reprogramming to engineer robust in situ vaccination

Jing Zhu, Meizhen Zhou, Yuxin Jin, Yunyun Wu, Hongrui Zhu, Lunli Xiang, Jie Sun, Sheng Zhao, Jixi Zhang

Acta Pharmaceutica Sinica B · Published 1 October 2026 · DOI 10.1016/j.apsb.2026.09.030

Open full textCite this paper

In brief

“From a single phenolic precursor to an all-in-one therapeutic cascade: Spatially programmed photoenzymatic immunotherapy and deep-tumor metabolic reprogramming to engineer robust in situ vaccination” is a 2026 journal article by Jing Zhu and 8 co-authors, published in Acta Pharmaceutica Sinica B. OpenAlex counts 0 citations as of 17 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Acta Pharmaceutica Sinica B.

Citations
0
References
61
Authors
9

Abstract

In situ vaccination, while promising for tumor immunotherapy, is fundamentally challenged by the inability to spatiotemporally coordinate immunogenic killing in vascularized regions with immunometabolism reprogramming in hypoxic depths without exacerbating immunosuppression. Here, we report an in situ nanovaccine platform comprising a cascade-unlocking nanoassembly derived from a single bioactive precursor (caffeic acid, CA), designed to overcome these barriers. This platform is engineered through a copper-catalyzed polymerization-assembly process, which bypasses the cumbersome integration of multiple pre-synthesized functional components. Specifically, Cu 2+ -driven co-assembly of CA monomers with semiquinone-rich oligomer nanoparticles yields a Cu 2+ -quenched system. Upon tumor accumulation, elevated glutathione triggers disassembly and reduces Cu 2+ to Cu + , restoring electron transfer and photoenzymatic activity in stabilized semiquinone radicals (lasting over 8 weeks). The released oligomeric units penetrate hypoxic regions, inducing immunogenic tumor killing and repolarizing M2-like macrophages via hypoxia-tolerant photoenzymatic catalysis. Concurrently, Cu + ions and CA monomers are disseminated in deeper tumor cores, disrupting mitochondrial metabolism, activating AMPK, and promoting PD-L1 degradation. By coordinating periphery-focused catalytic immunoactivation with core-targeted metabolic–immune reprogramming, this system amplifies T cell activation (9.3-fold) and suppresses both primary and metastatic (98.9%) tumors. This all-in-one nanoplatform enables spatiotemporally programmed in situ vaccination, disrupting immunosuppressive niches and initiating self-reinforcing antitumor immunity across heterogeneous tumors.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Zhu, J., Zhou, M., Jin, Y., Wu, Y., Zhu, H., Xiang, L., Sun, J., Zhao, S., & Zhang, J. (2026). From a single phenolic precursor to an all-in-one therapeutic cascade: Spatially programmed photoenzymatic immunotherapy and deep-tumor metabolic reprogramming to engineer robust in situ vaccination. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2026.09.030

MLA 9

Zhu, Jing, et al. “From a single phenolic precursor to an all-in-one therapeutic cascade: Spatially programmed photoenzymatic immunotherapy and deep-tumor metabolic reprogramming to engineer robust in situ vaccination.” Acta Pharmaceutica Sinica B, 2026. https://doi.org/10.1016/j.apsb.2026.09.030.

Chicago

Zhu, Jing, Meizhen Zhou, Yuxin Jin, Yunyun Wu, Hongrui Zhu, Lunli Xiang, Jie Sun, Sheng Zhao, and Jixi Zhang. 2026. “From a single phenolic precursor to an all-in-one therapeutic cascade: Spatially programmed photoenzymatic immunotherapy and deep-tumor metabolic reprogramming to engineer robust in situ vaccination.” Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2026.09.030.

Harvard

Zhu, J. et al. (2026) ‘From a single phenolic precursor to an all-in-one therapeutic cascade: Spatially programmed photoenzymatic immunotherapy and deep-tumor metabolic reprogramming to engineer robust in situ vaccination’, Acta Pharmaceutica Sinica B. doi:10.1016/j.apsb.2026.09.030.

IEEE

J. Zhu et al., “From a single phenolic precursor to an all-in-one therapeutic cascade: Spatially programmed photoenzymatic immunotherapy and deep-tumor metabolic reprogramming to engineer robust in situ vaccination,” Acta Pharmaceutica Sinica B, 2026, doi: 10.1016/j.apsb.2026.09.030.

BibTeX

@article{zhu2026from,
  title     = {{From a single phenolic precursor to an all-in-one therapeutic cascade: Spatially programmed photoenzymatic immunotherapy and deep-tumor metabolic reprogramming to engineer robust in situ vaccination}},
  author    = {Zhu, Jing and Zhou, Meizhen and Jin, Yuxin and Wu, Yunyun and Zhu, Hongrui and Xiang, Lunli and Sun, Jie and Zhao, Sheng and Zhang, Jixi},
  journal   = {Acta Pharmaceutica Sinica B},
  year      = {2026},
  doi       = {10.1016/j.apsb.2026.09.030},
  url       = {https://doi.org/10.1016/j.apsb.2026.09.030}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics

  • in situ vaccination
  • caffeic acid
  • tumor hypoxia
  • M2 macrophage polarization
  • mitochondrial metabolism
  • AMPK activation
  • PD-L1 degradation
  • T cell activation

Work with this paper

Most-cited papers in Engineering

All highly cited Engineering papers

Questions about this paper

How do I cite this paper in APA style?

Zhu, J., Zhou, M., Jin, Y., Wu, Y., Zhu, H., Xiang, L., Sun, J., Zhao, S., & Zhang, J. (2026). From a single phenolic precursor to an all-in-one therapeutic cascade: Spatially programmed photoenzymatic immunotherapy and deep-tumor metabolic reprogramming to engineer robust in situ vaccination. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2026.09.030

How many times has this paper been cited?

0 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Acta Pharmaceutica Sinica B: sign in and open the full text from this page.

Who wrote this paper?

Jing Zhu, Meizhen Zhou, Yuxin Jin, Yunyun Wu, Hongrui Zhu, Lunli Xiang, Jie Sun, Sheng Zhao, Jixi Zhang.

What is the DOI of this paper?

10.1016/j.apsb.2026.09.030, permanently at https://doi.org/10.1016/j.apsb.2026.09.030. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.